OncLive TV

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Axitinib and Sorafenib Trial Hazard Ratio

Dr. Howard Scher from Memorial Sloan-Kettering on Circulating Tumor Cells in Prostate Cancer

Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial

Dr. Sonali Smith director Lymphoma Program at the University of Chicago Medical Center Discusses Lymphoma in the Elderly

Dr. David Cella from Northwestern University Feinberg School of Medicine Explains the Increase in Quality of Life Assessments

Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells

Dr. Jeffrey Infante from Sarah Cannon Research Institute on the Next Step in Melanoma Research

Dr. Mark Kris from Memorial Sloan-Kettering Cancer Center Discusses the Pemetrexed Clincal Trial Results

Dr. Jack West from the Swedish Cancer Institute Discusses Crizotinib in ALK-NSCLC Trial Results

Dr. Axel Hoos Medical Lead in Immunology/Oncology at Bristol-Myers Squibb on a Possible Successor Drug to Ipilimumab

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Dr. David Cella from Northwestern University Feinberg School of Medicine on the Side Effect Focus of the Axitinib and Sorafenib Trial

Dr. Kris From Memorial Sloan-Kettering Cancer Center Discusses the Imatinib GIST Clinical Trial

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Dr. Jedd D. Wolchok From Memorial Sloan-Kettering Cancer Center on Patients That Had to Stop Treatment Early

Dr. Paz-Ares From Seville University Hospital Discusses the Use of Pemetrexed for NSCLC

Dr. Cella From Northwestern University Feinberg School of Medicine Discusses Axitinib and Sorafenib Axis Trial

Dr. Wolchok From Memorial Sloan-Kettering Cancer Center Explains the Future of Ipilimumab

Dr. Vogelzang From the Comprehensive Cancer Centers of Nevada on XL184's Effect on Bone Metastases.

Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes Candidates for Ipilimumab

Dr. Chapman from Memorial Sloan-Kettering Cancer Center on Vemurafenib Combination Therapies

Dr. Hoos From Bristol-Myers Squibb Discusses Key Points of the Ipilimumab Trial

Dr. Chapman From Memorial Sloan-Kettering Cancer Center Describes Recent Melanoma Advances

Dr. Virgo From American Cancer Society Shares the Results of the PCP/MO Barriers Study

Dr Kris From Memorial Sloan-Kettering Cancer Center Discusses Methotrexate in Acute Lymphocytic Leukemia

Dr Paz-Ares from Seville University Hospital Discusses Pemetrexed Clinical Trial

Dr. Chapman From Memorial Sloan-Kettering Describes the Vemurafenib Clinical Trial

Dr. Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib Trial Design

Dr. Infante from Sarah Cannon Research Institute on the Future of BRAF Inhibitors in Melanoma

Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses the Progress of gastrointestinal stromal tumors (GIST) Treatments